Approaches to clinical development of combination medicines in the Russian Federation and the Eurasian Economic Union in view of the requirements of the current legislation
In recent years, there has been an increasing interest in the development of combination medicines (fixed drug combinations) containing two or more active ingredients in a single dosage form. Therefore, there is an urgent need to develop an optimal programme of pre-authorisation clinical trials for...
Saved in:
| Main Author: | A. V. Dobrovolskiy |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)
2019-03-01
|
| Series: | Регуляторные исследования и экспертиза лекарственных средств |
| Subjects: | |
| Online Access: | https://www.vedomostincesmp.ru/jour/article/view/208 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Russian regulatory system for clinical trials is consistent with international approaches
by: Yu. N. Linkova
Published: (2023-12-01) -
REGULATORY STRATEGY OF CLINICAL DEVELOPMENT FOR FIXED COMBINATION MEDICINAL PRODUCTS
by: K. A. Yatsenko, et al.
Published: (2019-01-01) -
Conducting Pharmaceutical Inspections in the Russian Federation to Ensure Compliance with the EAEU GCP Requirements Is an Accepted Necessity
by: A. A. Trapkova
Published: (2023-06-01) -
Actions of the Manufacturers of Herbal and Other High-Demand Medicinal Products According to the EAEU Authorisation Procedures: Practical Recommendations
by: E. M. Rychikhina
Published: (2024-04-01) -
Technology forecast: advanced therapies in late clinical research, EMA approval or clinical application via hospital exemption
by: Claudia Eder, et al.
Published: (2019-01-01)